# EDGAR Filing Document

**Accession Number:** 0001753347
**File Stem:** 0001493152-26-008353
**Filing Date:** 2026-2
**Character Count:** 3311
**Document Hash:** 27fc0f2003a9b13062d38910de54d00d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-008353.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001493152-26-008353

**CONFORMED SUBMISSION TYPE**: RW

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Edison Oncology Holding Corp
- **CENTRAL INDEX KEY:** 0001753347
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831614120
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** RW

**SEC ACT:**
- **SEC FILE NUMBER:** 333-291852
- **FILM NUMBER:** 26701380

**BUSINESS ADDRESS:**
- **STREET 1:** 3475 EDISON WAY
- **STREET 2:** SUITE R
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** (650)690-1927

**MAIL ADDRESS:**
- **STREET 1:** 3475 EDISON WAY
- **STREET 2:** SUITE R
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

February 27, 2026

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Edison Oncology Holding Corp.** |
|  | **Request for Withdrawal of Registration Statement on Form S-1** |
|  | **File No. 333-291852** |

---

Ladies and Gentlemen:

On November 28, 2024, Edison Oncology Holding Corp. (the "Company"), a Nevada corporation, filed a Registration Statement on Form S-1 (File No. 333-291852) (together with the amendments, exhibits and supplements thereto, the "Registration Statement") under the Securities Act of 1933, as amended (the "Securities Act"), with the Securities and Exchange Commission (the "Commission") for the registration of the Company's common shares in connection with its proposed initial public offering of securities. The Registration Statement was declared effective on January 30, 2026, and a post-effective amendment to the Registration Statement was filed under Rule 462(c) on February 13, 2026. No securities covered by the Registration Statement have been sold.

Pursuant to Rule 477 under the Securities Act, the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement as of the date hereof or as soon as practicable thereafter. The Company is seeking withdrawal of the Registration Statement as it does not intend to pursue the contemplated offering of securities covered by the Registration Statement at this time.

In accordance with Rule 457(p) under the Securities Act, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company's account to be offset against the filing fee for any future registration statement of the Company or an affiliate thereof.

If you have any questions, or if it would expedite your review in any way, please do not hesitate to contact the undersigned at (650) 690-1927 or Raul Silvestre of Silvestre Law Group at (818) 597-7552. We thank the staff of the Commission in advance for their assistance.

Sincerely,

---

| |
|:---|
| **Edison Oncology Holding Corp.** |
| */s/ Jeffrey Bacha* |
| Jeffrey Bacha |
| Chief Executive Officer and Director |

---

CC: Raul Silvestre at Silvestre Law Group, P.C.